Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of "Buy" by Brokerages

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) have been assigned a consensus rating of "Buy" from the ten brokerages that are currently covering the stock, Marketbeat.com reports. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $12.67.

Several equities analysts recently issued reports on the company. Raymond James Financial raised Compass Therapeutics to an "outperform" rating and set a $9.00 price objective for the company in a report on Tuesday, July 1st. HC Wainwright reaffirmed a "buy" rating and set a $24.00 price objective on shares of Compass Therapeutics in a report on Monday, April 21st. Guggenheim reduced their price objective on Compass Therapeutics from $12.00 to $10.00 and set a "buy" rating for the company in a report on Friday, May 9th. Leerink Partners raised Compass Therapeutics from a "market perform" rating to an "outperform" rating and lifted their price objective for the stock from $4.00 to $6.00 in a report on Wednesday, April 2nd. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $32.00 price objective on shares of Compass Therapeutics in a report on Monday, April 28th.

Compass Therapeutics Price Performance

Compass Therapeutics stock opened at $2.85 on Friday. Compass Therapeutics has a 1-year low of $0.87 and a 1-year high of $4.08. The company has a market cap of $394.11 million, a PE ratio of -6.95 and a beta of 1.48. The stock's 50 day moving average price is $2.29 and its 200 day moving average price is $2.32.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.12) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.12). On average, equities research analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Institutional Trading of Compass Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of CMPX. Tower Research Capital LLC TRC raised its stake in Compass Therapeutics by 298.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock valued at $25,000 after buying an additional 12,917 shares in the last quarter. Independent Advisor Alliance acquired a new stake in Compass Therapeutics during the fourth quarter valued at approximately $26,000. BNP Paribas Financial Markets acquired a new stake in shares of Compass Therapeutics during the 4th quarter worth approximately $27,000. Mariner LLC acquired a new stake in shares of Compass Therapeutics during the 4th quarter worth approximately $30,000. Finally, Strs Ohio acquired a new stake in shares of Compass Therapeutics during the 1st quarter worth approximately $34,000. Institutional investors and hedge funds own 68.43% of the company's stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.